Vorinostat is victorious in GVHD prevention

Research output: Contribution to journalComment/debate

2 Scopus citations

Abstract

In this issue of Blood, Choi et al describe the clinical efficacy of histone deacetylase inhibitor (HDACi) vorinostat in the prevention of severe acute graft-versus-host disease (aGVHD) in a high-risk setting: myeloablative, unrelated-donor allogeneic hematopoietic cell transplantation (HCT).1

Original languageEnglish (US)
Pages (from-to)1690-1691
Number of pages2
JournalBlood
Volume130
Issue number15
DOIs
StatePublished - Oct 12 2017

    Fingerprint

Cite this